Biotechnology

FluoGuide A/S Publishes Interim Report for the Period January - September 2023

November 29, 2023 2:20 AM

KØBENHAVN, DENMARK / ACCESSWIRE / November 29, 2023 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 29 November 2023 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 30 September 2023. The Q3 report is available as an attached document to this press release and on FluoGuide's website. In Q3 2023, FluoGuide completed patient recruitment for two clinical phase II trials of FG001, in aggressive...

Read more

Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States

November 28, 2023 8:15 AM

Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer Treatment SAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, and OncoZenge AB ("OncoZenge") (STO:ONCOZ), a clinical-stage company...

Read more

AmplifyBio Expands Its Vision: Launches Advanced Therapy Manufacturing Enablement Center in New Albany, Ohio

November 28, 2023 7:00 AM

NEW ALBANY, OH / ACCESSWIRE / November 28, 2023 / AmplifyBio, a leading contract research organization, is announcing the opening of a new business unit to further expand its reach into the manufacturing of next-generation therapies that include cell, gene, mRNA, and other advanced modalities. The Amplify Manufacturing Enablement Center (AMEC), located 30 minutes from their West Jefferson headquarters in New Albany, Ohio, will comprise...

Read more

AbTherx Appoints David Meininger, PhD, MBA as Chief Business Officer

November 28, 2023 6:00 AM

Biopharma executive with proven track record brings substantial strategy, business development, and licensing experience to AbTherx leadership team MOUNTAIN VIEW, CA / ACCESSWIRE / November 28, 2023 / AbTherx, a privately held biotech company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of David Meininger, PhD, MBA to the newly created position of Chief Business Officer. Dr....

Read more

Q2 Interim Report August-October 2023/2024

November 28, 2023 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / November 28, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Continued sales growth and several commercial agreements signed! SEK t Q2 23/24 Q2 22/23 May-Oct 23/24 May-Oct 22/23 Full year 22/23 Net sales 2,563 961 4,316 1,506 3,383 Operating profit (loss) -25,316 -23,310 -57,508 -43,973 -110,457 Profit (loss) for the period -25,684 -23,250 -57,949 -44,254 -110,492 Earnings per share, after...

Read more

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

November 27, 2023 9:40 PM

BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions, today announced the pricing of an underwritten public offering of 10,000,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each share of common stock (or...

Read more

Organicell Announces 1-for-200 Reverse Stock Split

November 27, 2023 5:00 PM

FORT LAUDERDALE, FL / ACCESSWIRE / November 27, 2023 / Organicell Regenerative Medicine Inc, (OTCQB:OCEL) ("Organicell" or the "Company"), today announced that it is implementing a 1-for-200 Reverse Split of the Company's common stock (the "Reverse Split") effective as of the close of business on November 27, 2023. As a result, every 200 pre-Reverse Split shares of common stock outstanding will automatically combine into one new share of...

Read more

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study

November 27, 2023 9:05 AM

DehydraTECHTM-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus®: Sustained higher levels of semaglutide in blood; Faster achievement of peak drug delivery; and Reduced side effects. KELOWNA, BC / ACCESSWIRE / November 27, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive interim results from a human...

Read more

Merge by Merative Partners with Indica Labs to Bring Digital Pathology into Enterprise Imaging Solutions

November 27, 2023 8:00 AM

Joint solution enables healthcare providers to complete the longitudinal patient imaging record ANN ARBOR, MI and ALBUQUERQUE, NM / ACCESSWIRE / November 27, 2023 / Merge by Merative, an industry leader in medical imaging solutions, signed an agreement with Indica Labs, a leading provider of AI-powered digital pathology solutions. This partnership will enable healthcare organizations to seamlessly integrate digital pathology into Merge imaging...

Read more

Invitation to Webcast for Q2 2023/2024

November 24, 2023 6:50 AM

UPPSALA, SE / ACCESSWIRE / November 24, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, publishes its interim report for the second quarter 2023/2024, on November 28 at 08:00 CET. The company invites you to a webcast on the same day at 15.00 CET. Anders Rylander, CEO, Warren Cresswell, President of Biovica Americas, Henrik Winther, SVP Business Development and Anders Morén, CFO will...

Read more

Announcement from Biovica International AB's Extra General Meeting

November 23, 2023 8:30 AM

UPPSALA, SE / ACCESSWIRE / November 23, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The extra general meeting of Biovica International AB (the "Company") was held today on 23 November 2023 and the following resolution was passed by the meeting. Amendments of the articles of association The extra general meeting resolved, in accordance with the board of directors' proposal, to amend the limits of the articles of association...

Read more

FluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology conference

November 21, 2023 11:00 AM

Oral presentation outlines positive efficacy and safety data Confirms interim data showing FG001 met primary endpoint, with cancer lit up in 16 /16 (100%) patients, and was very well tolerated Several applications for potential clinical benefit will be further explored Topline phase IIb results of FG001 in high-grade glioma expected later in November 2023 COPENHAGEN, DENMARK / ACCESSWIRE / November 21, 2023 // FluoGuide A/S ("FluoGuide" or the...

Read more

Easy Energy Systems To Exhibit At Organic Growers Summit In Monterey, CA

November 21, 2023 9:00 AM

MANKATO, MN / ACCESSWIRE / November 21, 2023 / Digital Utilities Ventures, Inc. (OTC PINK:DUTV), announces that its planned future affiliate, Easy Energy Systems, Inc., will be exhibiting at the Organic Growers Show in Monterey on November 29-30. The summit provides growers firsthand knowledge and information in a variety of areas ranging from Agtech to food safety to sustainability. Through engaging educational sessions, insightful Keynote...

Read more

Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare Effective 1st January 2024

November 21, 2023 4:30 AM

UPPSALA, SE / ACCESSWIRE / November 21, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that the Center for Medicare & Medicaid Services (CMS) after reviewing public comments, has agreed with the minority CDLT panel to crosswalk DiviTum TKa to reimbursement code 0058U. The comments CMS received included detailed information as to how these tests are similar enough to make...

Read more

Stem Cell Therapy Developed in Korea Begins Treatment for Parkinson's Disease Patients Worldwide in Japan

November 20, 2023 8:06 PM

Biostar Stem Cell Research Institute has received approval from Japan's Ministry of Health, Labor and Welfare to Treat Parkinson's Disease. The combination of intravenous and spinal cord cavity administration is expected to increase the effectiveness of the treatment. This therapy may also be effective for other incurable neurological diseases. The stem cells are cultured in special media produced by Nature Cell, an affiliate of Biostar Stem...

Read more

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

November 20, 2023 4:50 PM

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%) The key secondary endpoints assessing symptom reduction, TSS50 and absolute change in TSS, showed significant improvements for intermediate-risk patients (p Pelabresib plus ruxolitinib showed clinically meaningful anemia improvement versus placebo and...

Read more

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

November 20, 2023 4:05 PM

1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced favorable final results from a Phase 2b dose-ranging clinical study of the company's drug candidate, EB01 (daniluromer), as a...

Read more

Goldcup 34064 AB Announces Vironova BioAnalytics Acquired by Investor Group

November 20, 2023 1:50 PM

Vironova BioAnalytics AB Acquired by an investor syndicate, led by Quatre Lab, to expand its TEM services for the pharmaceutical industry; to be rebranded as QuTEM STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2023 / Vironova BioAnalytics, a leading provider of transmission electron microscopy (TEM) services, is pleased to announce its acquisition led by QuatreLab (a quality control company created by Columbus Venture Partners) with the...

Read more

Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program

November 20, 2023 12:00 PM

NEW YORK, NY / ACCESSWIRE / November 20, 2023 / Qrons Inc. (OTCQB:QRON) announced that Professor Shiri Navon-Venezia has agreed to join Qrons Scientific Advisory Board. Professor Venezia is Professor of Microbiology, Head of Bacterial Pathogens & Antibiotic Resistance Lab in Ariel University. Her areas of expertise are Pathogenesis of multidrug resistant bacteria, molecular mechanisms of antibiotic resistance, genetic elements and their role in...

Read more

Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure

November 20, 2023 9:10 AM

Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. Progress ALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure. The purpose of the amended OTC Annual Report filed today is to include the...

Read more